A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(20 sites)
China
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui Peking University First Hospital, Beijing, Beijing Municipality Peking University People Hospital, Beijing, Beijing Municipality Beijing Tiantan Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Zhujiang Hospital Affiliated to Southern Medical University, Guangzhou, Guangdong Shenzhen Second People's Hospital, Shenzhen, Guangdong Liuzhou People's Hospital, Liuchow, Guangxi Liuzhou Workers's Hospital, Liuchow, Guangxi The Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou The Central Hospital of Wuhan, Wuhan, Hubei Tongji Hospital, Tongji Medical College of HUST, Wuhan, Hubei Nanhua Hospital Affiliated to University of south China, Hengyang, Hunan The Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality Linfen Central Hospital, Linfen, Shanxi Yuncheng Central Hospital, Yuncheng, Shanxi Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang Last updated October 2024